Targeting irradiation‐induced mitogen‐activated protein kinase activation in vitro and in an ex vivo model for human head and neck cancer

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Head and Neck

• Publication date

  2016-02-26

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/hed.24376PMID 26918677
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phosphorylation of AKT(Ser473) serves as an independent prognostic marker for radiosensitivity in advanced head and neck squamous cell carcinoma

  2015cited by this paper
• Radiation Oncology In Vitro: Trends to Improve Radiotherapy through Molecular Targets

  2014cited by this paper
• Increased radioresistance via G12S K‐Ras by compensatory upregulation of MAPK and PI3K pathways in epithelial cancer

  2013cited by this paper
• Overexpression of TOB1 confers radioprotection to bronchial epithelial cells through the MAPK/ERK pathway.

  2013cited by this paper
• Reactive oxygen species activation of MAPK pathway results in VEGF upregulation as an undesired irradiation response.

  2013cited by this paper
• Mitogen-activated protein kinases and their role in radiation response.

  2013cited by this paper
• Slice cultures from head and neck squamous cell carcinoma: a novel test system for drug susceptibility and mechanisms of resistance

  2013cited by this paper
• Tumor reoxygenation following administration of Mitogen-Activated Protein Kinase inhibitors: a rationale for combination with radiation therapy.

  2012cited by this paper
• The molecular pathogenesis of head and neck squamous cell carcinoma.

  2012cited by this paper
• Cotargeting MAPK and PI3K Signaling with Concurrent Radiotherapy as a Strategy for the Treatment of Pancreatic Cancer

  2012cited by this paper
• Phosphorylation of p53 modifies sensitivity to ionizing radiation.

  2011cited by this paper
• TP53 Disruptive Mutations Lead to Head and Neck Cancer Treatment Failure through Inhibition of Radiation-Induced Senescence

  2011cited by this paper
• Comprehensive Predictive Biomarker Analysis for MEK Inhibitor GSK1120212

  2011cited by this paper
• Activation of mitogen‐activated protein kinase extracellular signal‐related kinase in head and neck squamous cell carcinomas after irradiation as part of a rescue mechanism

  2011cited by this paper
• Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral MAPK/ERK Kinase Inhibitor PD-0325901 in Patients with Advanced Cancers

  2010cited by this paper
• Anti-EMMPRIN antibody treatment of head and neck squamous cell carcinoma in an ex-vivo model

  2010cited by this paper
• The Discovery of the Benzhydroxamate MEK Inhibitors CI‐1040 and PD 0325901.

  2009cited by this paper
• Molecular HPV Typing as a Diagnostic Tool to Discriminate Primary From Metastatic Squamous Cell Carcinoma of the Lung

  2009cited by this paper
• BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines.

  2008cited by this paper
• Augmentation of radiation response by panitumumab in models of upper aerodigestive tract cancer.

  2008cited by this paper
• Open Access Research

  2008cited by this paper
• Alterations in the p53 pathway and their association with radio- and chemosensitivity in head and neck squamous cell carcinoma.

  2008cited by this paper
• The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901.

  2008cited by this paper
• Potent Inhibition of Thyroid Cancer Cells by the MEK Inhibitor PD0325901 and Its Potentiation by Suppression of the PI3K and NF-κB Pathways

  2008cited by this paper
• TP53 mutations and survival in squamous-cell carcinoma of the head and neck.

  2007cited by this paper
• p53 regulates ERK activation in carboplatin induced apoptosis in cervical carcinoma: A novel target of p53 in apoptosis

  2007cited by this paper
• Counting colonies of clonogenic assays by using densitometric software

  2007cited by this paper
• Clinical experience of MEK inhibitors in cancer therapy.

  2007cited by this paper
• Recent advances of MEK inhibitors and their clinical progress.

  2007cited by this paper
• Extracellular signal-related kinase positively regulates ataxia telangiectasia mutated, homologous recombination repair, and the DNA damage response.

  2007cited by this paper
• Clonogenic assay of cells in vitro

  2006cited by this paper
• Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery.

  2005cited by this paper
• A phase 1–2 clinical study of a second generation oral MEK inhibitor, PD 0325901 in patients with advanced cancer

  2005cited by this paper
• Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies.

  2005cited by this paper
• Radioresistance in Oral Squamous Cell Carcinoma With p 53 DNA Contact Mutation

  2003cited by this paper
• Molecular pathogenesis of head and neck squamous cell carcinoma

  2003cited by this paper
• Roles of ERBB family receptor tyrosine kinases, and downstream signaling pathways, in the control of cell growth and survival.

  2002cited by this paper
• Modulation of molecular targets to enhance radiation.

  2000cited by this paper
• Effect of Extracellular Signal-regulated Kinase on p53 Accumulation in Response to Cisplatin*

  2000cited by this paper
• Phosphorylation of murine p53 at ser-18 regulates the p53 responses to DNA damage.

  2000cited by this paper
• Signal Transduction and Cellular Radiation Responses

  2000cited by this paper
• p38 Kinase Mediates UV-induced Phosphorylation of p53 Protein at Serine 389*

  1999cited by this paper
• The p38MAPK inhibitor SB203580 alleviates ultraviolet-induced phosphorylation at serine 389 but not serine 15 and activation of p53.

  1999cited by this paper
• JNK targets p53 ubiquitination and degradation in nonstressed cells.

  1998cited by this paper
• DNA damage induces phosphorylation of the amino terminus of p53.

  1997cited by this paper
• p53 mutation does not correlate with radiosensitivity in 24 head and neck cancer cell lines.

  1993cited by this paper
• Participation of p53 protein in the cellular response to DNA damage.

  1991cited by this paper
• Radiation Oncology Intensity Modulated Radiotherapy (imrt) in the Postoperative Treatment of an Adenocarcinoma of the Endometrium Complicated by a Pelvic Kidney

  year unknowncited by this paper

• Understanding the Tumor Microenvironment and Therapy Resistance in Head and Neck Squamous Cell Carcinoma

  2025cites this paper
• Irradiation-induced cellular senescence is linked to pro-survival signaling and checkpoint regulation in a 2D and 3D model for head and neck cancer

  2025cites this paper
• Xeno-free alternatives to the use of fetal bovine serum in head and neck cancer explant culture

  2025influential citation
• MYC Overexpression Enhances Sensitivity to MEK Inhibition in Head and Neck Squamous Cell Carcinoma

  2025cites this paper
• Key signalling pathways in head and neck squamous cell carcinoma: mechanisms and therapeutic targets.

  2025cites this paper
• Synthesis of 5-hydroxyisatin thiosemicarbazones, spectroscopic investigation, protein-ligand docking, and in vitro anticancer activity.

  2024cites this paper
• Targeted therapy for head and neck cancer: signaling pathways and clinical studies

  2023cites this paper
• Mechanisms of Honeysuckle Against Triple-negative Breast Cancer Based on Network Pharmacology and Molecular Docking

  2023cites this paper
• Modulation of PD-L1 expression by standard therapy in head and neck cancer cell lines and exosomes

  2023cites this paper
• Biomarkers of radioresistance in head and neck squamous cell carcinomas

  2022influential citation
• Patient derived ex vivo tissue slice cultures demonstrate a profound DNA double-strand break repair defect in HPV-positive oropharyngeal head and neck cancer.

  2022cites this paper
• Kinomic comparison of snap frozen and ex vivo-cultured head and neck tumors.

  2021cites this paper
• Mitogen‐activated protein kinase inhibition‐induced modulation of epidermal growth factor receptor signaling in human head and neck squamous cell carcinoma

  2021cites this paper
• Precision Medicine Gains Momentum: Novel 3D Models and Stem Cell-Based Approaches in Head and Neck Cancer

  2021cites this paper
• Relevance of humanized three-dimensional tumor tissue models: a descriptive systematic literature review

  2020cites this paper
• Ex Vivo Culture Models to Indicate Therapy Response in Head and Neck Squamous Cell Carcinoma

  2020cites this paper
• Organotypic Co-Cultures as a Novel 3D Model for Head and Neck Squamous Cell Carcinoma

  2020cites this paper
• Dual effects of active ERK in cancer: A potential target for enhancing radiosensitivity

  2020cites this paper
• Adaptive ERK signalling activation in response to therapy and in silico prognostic evaluation of EGFR-MAPK in HNSCC

  2020cites this paper
• Regulation of submaxillary gland androgen-regulated protein 3A via estrogen receptor 2 in radioresistant head and neck squamous cell carcinoma cells

  2017cites this paper
• Mitogen-activated protein kinase signaling pathway in oral cancer.

  2017cites this paper
• Präklinische Modelle für Kopf-Hals-Tumoren

  2016cites this paper
• Integrating transcriptome and proteome profiling: Strategies and applications

  2016cites this paper
• [Preclinical models in head and neck tumors : Evaluation of cellular and molecular resistance mechanisms in the tumor microenvironment].

  2016cites this paper